CAR T Cells Targeting FLT3 on AML Confer Potent Anti-Leukemic Activity and Act Synergistically with the FLT3 Inhibitor Midostaurin

被引：0
|
作者：
Jetani, Hardikkumar
Garcia-Cadenas, Irene
Nerreter, Thomas
Rydzek, Julian
Thomas, Simone
Herr, Wolfgang
Sierra, Jordi
Bonig, Halvard
Einsele, Hermann
Hudecek, Michael
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1351
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [21] Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
    Jorge Cortes
    Journal of Hematology & Oncology, 17 (1)
  • [22] Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
    Wang, Eunice S.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (04)
  • [23] Inhibition of FLT3 Expression by Green Tea Catechins in FLT3 Mutated-AML Cells
    Bui Thi Kim Ly
    Hoang Thanh Chi
    Yamagishi, Makoto
    Kano, Yasuhiko
    Hara, Yukihiko
    Nakano, Kazumi
    Sato, Yuko
    Watanabe, Toshiki
    PLOS ONE, 2013, 8 (06):
  • [24] Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition
    Dzama, Margarita M.
    Steiner, Marlene
    Rausch, Johanna
    Sasca, Daniel
    Schoenfeld, Jonas
    Kunz, Kerstin
    Taubert, Martha C.
    McGeehan, Gerard M.
    Chen, Chun-Wei
    Mupo, Annalisa
    Haehnel, Patricia
    Theobald, Matthias
    Kindler, Thomas
    Koche, Richard P.
    Vassiliou, George S.
    Armstrong, Scott A.
    Kuehn, Michael W. M.
    BLOOD, 2020, 136 (21) : 2442 - 2456
  • [25] Therapeutic targeting of FLT3 mutations in AML via menin-MLL1 and FLT3 inhibition
    Dzama, Margarita M.
    Taubert, Martha C.
    Kunz, Kerstin
    Rausch, Johanna
    Chen, Chun-Wei
    Mupo, Annalisa
    Theobald, Matthias
    Kindler, Thomas
    Koche, Richard P.
    Vassiliou, George S.
    Armstrong, Scott A.
    Kuehn, Michael W.
    CANCER RESEARCH, 2019, 79 (13)
  • [26] Glucocorticoids act synergistically with FLT3 inhibitors to enhance cell death in FLT3 mutant acute myeloid leukemia
    Gebru, Melat Tsegaye
    Wang, Hong-Gang
    Xavier, Jennifer
    CANCER RESEARCH, 2020, 80 (16)
  • [27] Sorafenib displays antiproliferative effects in FLT3 mutated as well as in wildtype FLT3 AML cells
    Schult, C.
    Sekora, A.
    Krohn, S.
    Schaab, C.
    Godl, K.
    Freund, M.
    Junghanss, C.
    ONKOLOGIE, 2011, 34 : 78 - 78
  • [28] Molecular targeted therapy with FLT3 inhibitor in AML
    Cortes, Jorge E.
    ANNALS OF ONCOLOGY, 2022, 33 : S455 - S455
  • [29] ERAS-601, a potent inhibitor of SHP2, synergistically enhances the activity of a FLT3 inhibitor, gilteritinib, in FLT3-mutated AML tumor models
    Martin, Leenus
    Patel, Roopal
    Zhang, Jingchuan
    Nevarez, Robin
    Congdon, Taylor
    Brail, Les
    Shoemaker, Robert
    CANCER RESEARCH, 2022, 82 (12)
  • [30] TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax
    Tyagi, Anudishi
    Jaggupilli, Appalaraju
    Ly, Stanley
    Yuan, Bin
    El-Dana, Fouad
    Hegde, Venkatesh L.
    Anand, Vivek
    Kumar, Bijender
    Puppala, Mamta
    Yin, Zheng
    Wong, Stephen T. C.
    Mollard, Alexis
    Vankayalapati, Hariprasad
    Foulks, Jason M.
    Warner, Steven L.
    Daver, Naval
    Borthakur, Gautam
    Battula, V. Lokesh
    LEUKEMIA, 2024, 38 (01) : 82 - 95
12345